Annual report

Period2023-01-21 → 2024-01-20

Filed2024-04-17

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 148

Metric	Value	Period	Scope	Source row
Revenue	¥213.4bn	2023-01-21 → 2024-01-20	Cons.	Net sales
Revenue	¥160.1bn	2022-01-21 → 2023-01-20	Cons.	Net sales
Revenue	¥162.6bn	2021-01-21 → 2022-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥158.2bn	2020-01-21 → 2021-01-20^d	Cons.	Net sales (5-year summary)
Revenue	¥168.3bn	2019-01-21 → 2020-01-20^d	Cons.	Net sales (5-year summary)
Operating income	¥3.7bn	2023-01-21 → 2024-01-20	Cons.	Operating income
Operating income	¥707m	2022-01-21 → 2023-01-20	Cons.	Operating income
Ordinary income	¥3.1bn	2023-01-21 → 2024-01-20	Cons.	Ordinary income
Ordinary income	¥591m	2022-01-21 → 2023-01-20	Cons.	Ordinary income
Ordinary income	¥5.7bn	2021-01-21 → 2022-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥5.7bn	2020-01-21 → 2021-01-20^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥2.9bn	2019-01-21 → 2020-01-20^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	¥5.6bn	2023-01-21 → 2024-01-20	Cons.	Income before income taxes
Profit before tax	¥1.1bn	2022-01-21 → 2023-01-20	Cons.	Income before income taxes
Net income (owners)	¥4.4bn	2023-01-21 → 2024-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥507m	2022-01-21 → 2023-01-20	Cons.	Profit loss attributable to owners of parent
Net income (owners)	¥4.0bn	2021-01-21 → 2022-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥3.2bn	2020-01-21 → 2021-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥1.8bn	2019-01-21 → 2020-01-20^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	¥4.6bn	2023-01-21 → 2024-01-20	Cons.	Profit loss
Net income	−¥490m	2022-01-21 → 2023-01-20	Cons.	Profit loss
Total assets	¥177.6bn	at 2024-01-20	Cons.	Assets
Total assets	¥164.2bn	at 2023-01-20	Cons.	Assets
Total assets	¥159.0bn	at 2022-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥157.6bn	at 2021-01-20^d	Cons.	Total assets (5-year summary)
Total assets	¥163.4bn	at 2020-01-20^d	Cons.	Total assets (5-year summary)
Total liabilities	¥86.1bn	at 2024-01-20	Cons.	Liabilities
Total liabilities	¥80.1bn	at 2023-01-20	Cons.	Liabilities
Net assets / equity	¥91.5bn	at 2024-01-20	Cons.	Net assets
Net assets / equity	¥84.1bn	at 2023-01-20	Cons.	Net assets
Net assets / equity	¥83.3bn	at 2022-01-20^d	Cons.	Net assets
Net assets / equity	¥82.6bn	at 2021-01-20^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥89.2bn	at 2020-01-20^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥32.4bn	at 2024-01-20	Cons.	Cash and deposits
Cash and deposits	¥27.2bn	at 2023-01-20	Cons.	Cash and deposits
Cash & equivalents	¥33.7bn	at 2024-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥29.2bn	at 2023-01-20	Cons.	Cash and cash equivalents
Cash & equivalents	¥30.1bn	at 2022-01-20^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥32.7bn	at 2021-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥30.3bn	at 2020-01-20^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	¥9.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥5.1bn	2022-01-21 → 2023-01-20	Cons.	Net cash provided by used in operating activities
Operating cash flow	¥8.1bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥12.5bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥11.5bn	2019-01-21 → 2020-01-20^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥1.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥5.0bn	2022-01-21 → 2023-01-20	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥6.5bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥7.6bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥15.5bn	2019-01-21 → 2020-01-20^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	−¥3.2bn	2023-01-21 → 2024-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥1.1bn	2022-01-21 → 2023-01-20	Cons.	Net cash provided by used in financing activities
Financing cash flow	−¥3.7bn	2021-01-21 → 2022-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥2.3bn	2020-01-21 → 2021-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	−¥4.1bn	2019-01-21 → 2020-01-20^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥140.77	2023-01-21 → 2024-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-16.2	2022-01-21 → 2023-01-20	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥127.1	2021-01-21 → 2022-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥100.66	2020-01-21 → 2021-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥54	2019-01-21 → 2020-01-20^d	Cons.	Basic earnings loss per share (5-year summary)
Net assets per share	¥2,843.99	at 2024-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,663.79	at 2023-01-20	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,645.36	at 2022-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,612.23	at 2021-01-20^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥2,670.68	at 2020-01-20^d	Cons.	Net assets per share (5-year summary)
Equity ratio	50.4%	at 2024-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	50.9%	at 2023-01-20	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	52.1%	at 2022-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	51.8%	at 2021-01-20^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	53.9%	at 2020-01-20^d	Cons.	Equity to asset ratio (5-year summary)
ROE	5.1%	2023-01-21 → 2024-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	-0.6%	2022-01-21 → 2023-01-20	Cons.	Rate of return on equity (5-year summary)
ROE	4.8%	2021-01-21 → 2022-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	3.8%	2020-01-21 → 2021-01-20^d	Cons.	Rate of return on equity (5-year summary)
ROE	2.0%	2019-01-21 → 2020-01-20^d	Cons.	Rate of return on equity (5-year summary)
Employees	5,182	at 2024-01-20	Cons.	Number of employees
Employees	4,122	at 2023-01-20	Cons.	Number of employees
Employees	4,029	at 2022-01-20^d	Cons.	Number of employees
Employees	3,922	at 2021-01-20^d	Cons.	Number of employees
Employees	4,160	at 2020-01-20^d	Cons.	Number of employees
Revenue	¥5.3bn	2023-01-21 → 2024-01-20	Standalone	Operating revenue1
Revenue	¥5.0bn	2022-01-21 → 2023-01-20	Standalone	Operating revenue1
Revenue	¥4.8bn	2021-01-21 → 2022-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥4.8bn	2020-01-21 → 2021-01-20^d	Standalone	Operating revenue1 (5-year summary)
Revenue	¥6.6bn	2019-01-21 → 2020-01-20^d	Standalone	Operating revenue1 (5-year summary)
Operating income	¥1.1bn	2023-01-21 → 2024-01-20	Standalone	Operating income
Operating income	¥1.7bn	2022-01-21 → 2023-01-20	Standalone	Operating income
Ordinary income	¥2.0bn	2023-01-21 → 2024-01-20	Standalone	Ordinary income
Ordinary income	¥2.3bn	2022-01-21 → 2023-01-20	Standalone	Ordinary income
Ordinary income	¥2.4bn	2021-01-21 → 2022-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥1.9bn	2020-01-21 → 2021-01-20^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥4.0bn	2019-01-21 → 2020-01-20^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	¥4.0bn	2023-01-21 → 2024-01-20	Standalone	Income before income taxes
Profit before tax	¥2.8bn	2022-01-21 → 2023-01-20	Standalone	Income before income taxes
Net income	¥2.9bn	2023-01-21 → 2024-01-20	Standalone	Profit loss
Net income	¥1.9bn	2022-01-21 → 2023-01-20	Standalone	Profit loss
Net income	¥1.4bn	2021-01-21 → 2022-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥899m	2020-01-21 → 2021-01-20^d	Standalone	Net income loss (5-year summary)
Net income	¥2.4bn	2019-01-21 → 2020-01-20^d	Standalone	Net income loss (5-year summary)
Total assets	¥124.8bn	at 2024-01-20	Standalone	Assets
Total assets	¥122.7bn	at 2023-01-20	Standalone	Assets
Total assets	¥122.2bn	at 2022-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥116.8bn	at 2021-01-20^d	Standalone	Total assets (5-year summary)
Total assets	¥119.1bn	at 2020-01-20^d	Standalone	Total assets (5-year summary)
Total liabilities	¥42.4bn	at 2024-01-20	Standalone	Liabilities
Total liabilities	¥42.3bn	at 2023-01-20	Standalone	Liabilities
Net assets / equity	¥82.4bn	at 2024-01-20	Standalone	Net assets
Net assets / equity	¥80.5bn	at 2023-01-20	Standalone	Net assets
Net assets / equity	¥80.1bn	at 2022-01-20^d	Standalone	Net assets
Net assets / equity	¥78.5bn	at 2021-01-20^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥84.7bn	at 2020-01-20^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥25.8bn	at 2024-01-20	Standalone	Cash and deposits
Cash and deposits	¥21.1bn	at 2023-01-20	Standalone	Cash and deposits
EPS (basic)	¥92.22	2023-01-21 → 2024-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥61.07	2022-01-21 → 2023-01-20	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥45.88	2021-01-21 → 2022-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥28.25	2020-01-21 → 2021-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥73.96	2019-01-21 → 2020-01-20^d	Standalone	Basic earnings loss per share (5-year summary)
Dividend per share	¥60	2023-01-21 → 2024-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2022-01-21 → 2023-01-20	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2021-01-21 → 2022-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2020-01-21 → 2021-01-20^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥60	2019-01-21 → 2020-01-20^d	Standalone	Dividend paid per share (5-year summary)
Net assets per share	¥2,618.07	at 2024-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,564.03	at 2023-01-20	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,559.09	at 2022-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,512.97	at 2021-01-20^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥2,570.8	at 2020-01-20^d	Standalone	Net assets per share (5-year summary)
Equity ratio	66.0%	at 2024-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2023-01-20	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	65.6%	at 2022-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	67.2%	at 2021-01-20^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	71.1%	at 2020-01-20^d	Standalone	Equity to asset ratio (5-year summary)
ROE	3.6%	2023-01-21 → 2024-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	2.4%	2022-01-21 → 2023-01-20	Standalone	Rate of return on equity (5-year summary)
ROE	1.8%	2021-01-21 → 2022-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	1.1%	2020-01-21 → 2021-01-20^d	Standalone	Rate of return on equity (5-year summary)
ROE	2.8%	2019-01-21 → 2020-01-20^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	16,568,000	at 2024-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2023-01-20	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2022-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2021-01-20^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	16,568,000	at 2020-01-20^d	Standalone	Total number of issued shares (5-year summary)
Employees	39	at 2024-01-20	Standalone	Number of employees
Employees	26	at 2023-01-20	Standalone	Number of employees
Employees	23	at 2022-01-20^d	Standalone	Number of employees
Employees	19	at 2021-01-20^d	Standalone	Number of employees
Employees	21	at 2020-01-20^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 93

Segment	Item	Period	Value
Reconciling Itemsreconciling	capex	2023-01-21 → 2024-01-20	¥926m
Reconciling Itemsreconciling	depreciation	2023-01-21 → 2024-01-20	¥793m
Reconciling Itemsreconciling	revenue	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	revenue intersegment	2023-01-21 → 2024-01-20	−¥366m
Reconciling Itemsreconciling	segment assets	at 2024-01-20	¥44.8bn
Reconciling Itemsreconciling	segment profit	2023-01-21 → 2024-01-20	−¥2.2bn
Domestic Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥9.4bn
Domestic Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥5.1bn
Domestic Beverage Businessreportable segment	employees	at 2024-01-20	3776 pure
Domestic Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥153.6bn
Domestic Beverage Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥26m
Domestic Beverage Businessreportable segment	segment assets	at 2024-01-20	¥74.7bn
Domestic Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥4.3bn
Dy Do Pharmareportable segment	capex	2023-01-21 → 2024-01-20	¥57m
Dy Do Pharmareportable segment	depreciation	2023-01-21 → 2024-01-20	¥9m
Dy Do Pharmareportable segment	employees	at 2024-01-20	14 pure
Dy Do Pharmareportable segment	segment assets	at 2024-01-20	¥381m
Dy Do Pharmareportable segment	segment profit	2023-01-21 → 2024-01-20	−¥796m
Food Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥638m
Food Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥848m
Food Businessreportable segment	employees	at 2024-01-20	272 pure
Food Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥20.7bn
Food Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥7m
Food Businessreportable segment	segment assets	at 2024-01-20	¥21.4bn
Food Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥993m
International Beverage Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥1.2bn
International Beverage Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥859m
International Beverage Businessreportable segment	employees	at 2024-01-20	749 pure
International Beverage Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥26.4bn
International Beverage Businessreportable segment	segment assets	at 2024-01-20	¥16.7bn
International Beverage Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥1.1bn
Pharmaceutical Related Businessreportable segment	capex	2023-01-21 → 2024-01-20	¥483m
Pharmaceutical Related Businessreportable segment	depreciation	2023-01-21 → 2024-01-20	¥1.2bn
Pharmaceutical Related Businessreportable segment	employees	at 2024-01-20	332 pure
Pharmaceutical Related Businessreportable segment	revenue	2023-01-21 → 2024-01-20	¥13.0bn
Pharmaceutical Related Businessreportable segment	revenue external	2023-01-21 → 2024-01-20	¥12.6bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2023-01-21 → 2024-01-20	¥331m
Pharmaceutical Related Businessreportable segment	segment assets	at 2024-01-20	¥19.5bn
Pharmaceutical Related Businessreportable segment	segment profit	2023-01-21 → 2024-01-20	¥367m
—segment total	capex	2023-01-21 → 2024-01-20	¥11.7bn
—segment total	depreciation	2023-01-21 → 2024-01-20	¥8.0bn
—segment total	revenue	2023-01-21 → 2024-01-20	¥213.7bn
—segment total	revenue external	2023-01-21 → 2024-01-20	¥213.4bn
—segment total	revenue intersegment	2023-01-21 → 2024-01-20	¥366m
—segment total	segment assets	at 2024-01-20	¥132.7bn
—segment total	segment profit	2023-01-21 → 2024-01-20	¥5.9bn
Reconciling Itemsreconciling	capex	2022-01-21 → 2023-01-20	¥1.5bn
Reconciling Itemsreconciling	depreciation	2022-01-21 → 2023-01-20	¥373m
Reconciling Itemsreconciling	revenue	2022-01-21 → 2023-01-20	−¥636m
Reconciling Itemsreconciling	revenue intersegment	2022-01-21 → 2023-01-20	−¥636m
Reconciling Itemsreconciling	segment assets	at 2023-01-20	¥47.8bn
Reconciling Itemsreconciling	segment profit	2022-01-21 → 2023-01-20	−¥1.6bn
Domestic Beverage Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥8.3bn
Domestic Beverage Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥4.6bn
Domestic Beverage Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥109.8bn
Domestic Beverage Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥109.7bn
Domestic Beverage Businessreportable segment	revenue intersegment	2022-01-21 → 2023-01-20	¥25m
Domestic Beverage Businessreportable segment	segment assets	at 2023-01-20	¥60.4bn
Domestic Beverage Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	¥2.8bn
Dy Do Pharmareportable segment	capex	2022-01-21 → 2023-01-20	¥1m
Dy Do Pharmareportable segment	depreciation	2022-01-21 → 2023-01-20	¥2m
Dy Do Pharmareportable segment	segment assets	at 2023-01-20	¥1.1bn
Dy Do Pharmareportable segment	segment profit	2022-01-21 → 2023-01-20	−¥499m
Food Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥877m
Food Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥848m
Food Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥19.6bn
Food Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥19.6bn
Food Businessreportable segment	revenue intersegment	2022-01-21 → 2023-01-20	¥8m
Food Businessreportable segment	segment assets	at 2023-01-20	¥21.8bn
Food Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	¥765m
International Beverage Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥522m
International Beverage Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥718m
International Beverage Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥18.9bn
International Beverage Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥18.9bn
International Beverage Businessreportable segment	segment assets	at 2023-01-20	¥13.5bn
International Beverage Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	−¥1.1bn
Pharmaceutical Related Businessreportable segment	capex	2022-01-21 → 2023-01-20	¥220m
Pharmaceutical Related Businessreportable segment	depreciation	2022-01-21 → 2023-01-20	¥1.2bn
Pharmaceutical Related Businessreportable segment	revenue	2022-01-21 → 2023-01-20	¥12.5bn
Pharmaceutical Related Businessreportable segment	revenue external	2022-01-21 → 2023-01-20	¥11.9bn
Pharmaceutical Related Businessreportable segment	revenue intersegment	2022-01-21 → 2023-01-20	¥601m
Pharmaceutical Related Businessreportable segment	segment assets	at 2023-01-20	¥19.7bn
Pharmaceutical Related Businessreportable segment	segment profit	2022-01-21 → 2023-01-20	¥347m
—segment total	capex	2022-01-21 → 2023-01-20	¥9.9bn
—segment total	depreciation	2022-01-21 → 2023-01-20	¥7.4bn
—segment total	revenue	2022-01-21 → 2023-01-20	¥160.8bn
—segment total	revenue external	2022-01-21 → 2023-01-20	¥160.1bn
—segment total	revenue intersegment	2022-01-21 → 2023-01-20	¥636m
—segment total	segment assets	at 2023-01-20	¥116.4bn
—segment total	segment profit	2022-01-21 → 2023-01-20	¥2.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,755

Item	Context	Value	Unit
Non audit fees reporting company network firms	CurrentYearDuration	0	JPY
Audit fees consolidated subsidiaries network firms	Prior1YearDuration	6000000	JPY
Non audit fees consolidated subsidiaries network firms	Prior1YearDuration	6000000	JPY
Audit fees consolidated subsidiaries network firms	CurrentYearDuration	1000000	JPY
Non audit fees consolidated subsidiaries network firms	CurrentYearDuration	0	JPY
Audit fees total network firms	Prior1YearDuration	6000000	JPY
Non audit fees total network firms	Prior1YearDuration	6000000	JPY
Audit fees total network firms	CurrentYearDuration	1000000	JPY
Non audit fees total network firms	CurrentYearDuration	1000000	JPY
Total amount of remuneration etc remuneration etc by category of directors and other officers	CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember	170000000	JPY
Base remuneration remuneration etc by category of directors and other officers	CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember	129000000	JPY
Performance linked bonus remuneration by category of directors and other officers	CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember	19000000	JPY
Restricted share awards remuneration etc by category of directors and other officers	CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember	2000000	JPY
Trust type stock compensation remuneration by category of directors and other officers	CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember	18000000	JPY
Number of directors and other officers remuneration etc by category of directors and other officers	CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember	3
Total amount of remuneration etc remuneration etc by category of directors and other officers	CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember	16000000	JPY
Base remuneration remuneration etc by category of directors and other officers	CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember	16000000	JPY
Performance linked bonus remuneration by category of directors and other officers	CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember	－	JPY
Restricted share awards remuneration etc by category of directors and other officers	CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember	－	JPY
Trust type stock compensation remuneration by category of directors and other officers	CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember	－	JPY
Number of directors and other officers remuneration etc by category of directors and other officers	CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember	2
Total amount of remuneration etc remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideDirectorsMember	24000000	JPY
Base remuneration remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideDirectorsMember	24000000	JPY
Performance linked bonus remuneration by category of directors and other officers	CurrentYearDuration_OutsideDirectorsMember	－	JPY
Restricted share awards remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideDirectorsMember	－	JPY
Trust type stock compensation remuneration by category of directors and other officers	CurrentYearDuration_OutsideDirectorsMember	－	JPY
Number of directors and other officers remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideDirectorsMember	4
Total amount of remuneration etc remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideCorporateAuditorsMember	17000000	JPY
Base remuneration remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideCorporateAuditorsMember	17000000	JPY
Performance linked bonus remuneration by category of directors and other officers	CurrentYearDuration_OutsideCorporateAuditorsMember	－	JPY
Restricted share awards remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideCorporateAuditorsMember	－	JPY
Trust type stock compensation remuneration by category of directors and other officers	CurrentYearDuration_OutsideCorporateAuditorsMember	－	JPY
Number of directors and other officers remuneration etc by category of directors and other officers	CurrentYearDuration_OutsideCorporateAuditorsMember	3
Total amount of remuneration etc paid by group remuneration etc paid by group to each director or other officer	CurrentYearDuration_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember	147000000	JPY
Number of issues shares not listed investment shares held for purposes other than pure investment reporting company	CurrentYearInstant	14
Carrying amount shares not listed investment shares held for purposes other than pure investment reporting company	CurrentYearInstant	131000000	JPY
Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company	CurrentYearInstant	11
Carrying amount shares other than those not listed investment shares held for purposes other than pure investment reporting company	CurrentYearInstant	7814000000	JPY
Number of issues whose number of shares increased shares not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	－
Total acquisition cost for increased shares shares not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	－	JPY
Number of issues whose number of shares increased shares other than those not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	1
Total acquisition cost for increased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	0	JPY
Number of issues whose number of shares decreased shares not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	－
Total sale amount for decreased shares shares not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	－	JPY
Number of issues whose number of shares decreased shares other than those not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	3
Total sale amount for decreased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company	CurrentYearDuration	2501000000	JPY
Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company	CurrentYearInstant_Row1Member	5880216
Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company	Prior1YearInstant_Row1Member	8411216
Book value details of specified investment equity securities held for purposes other than pure investment reporting company	CurrentYearInstant_Row1Member	4830000000	JPY
Book value details of specified investment equity securities held for purposes other than pure investment reporting company	Prior1YearInstant_Row1Member	6273000000	JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2023-01-20	pass
balance sheet identity	consolidated 2024-01-20	pass rounding
balance sheet identity	non_consolidated 2023-01-20	pass
balance sheet identity	non_consolidated 2024-01-20	pass rounding
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2022-01-20	pass
statement vs summary · net assets	consolidated 2023-01-20	pass
statement vs summary · net assets	consolidated 2024-01-20	pass
statement vs summary · net assets	non_consolidated 2022-01-20	pass
statement vs summary · net assets	non_consolidated 2023-01-20	pass
statement vs summary · net assets	non_consolidated 2024-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2022-01-21/2023-01-20	pass
statement vs summary · net income attributable to parent	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · operating cash flow	consolidated 2022-01-21/2023-01-20	pass
statement vs summary · operating cash flow	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	consolidated 2022-01-21/2023-01-20	pass
statement vs summary · revenue	consolidated 2023-01-21/2024-01-20	pass
statement vs summary · revenue	non_consolidated 2022-01-21/2023-01-20	pass
statement vs summary · revenue	non_consolidated 2023-01-21/2024-01-20	pass
statement vs summary · total assets	consolidated 2023-01-20	pass
statement vs summary · total assets	consolidated 2024-01-20	pass
statement vs summary · total assets	non_consolidated 2023-01-20	pass
statement vs summary · total assets	non_consolidated 2024-01-20	pass